Provided by Tiger Fintech (Singapore) Pte. Ltd.

CervoMed

6.44
+0.650011.23%
Post-market: 6.690.2500+3.88%19:59 EDT
Volume:9.01M
Turnover:56.88M
Market Cap:53.15M
PE:-4.02
High:6.76
Open:5.74
Low:5.40
Close:5.79
Loading ...

CervoMed's dementia drug fails to meet mid-stage trial goals

Reuters
·
10 Dec 2024

CervoMed Inc - Neflamapimod Fails to Meet Primary and Secondary Endpoints

THOMSON REUTERS
·
10 Dec 2024

CervoMed Inc - Full Data Set From Rewind-Lb Trial Expected in January 2025

THOMSON REUTERS
·
10 Dec 2024

CervoMed Inc - Trial Participants Continue Neflamapimod in Open-Label Extension

THOMSON REUTERS
·
10 Dec 2024

CervoMed Announces Topline Data From Rewind-Lb Phase 2B Clinical Trial in Patients With Dementia With Lewy Bodies

THOMSON REUTERS
·
10 Dec 2024

CervoMed Inc - Target Plasma Drug Concentrations Not Achieved in Trial

THOMSON REUTERS
·
10 Dec 2024

CervoMed Inc - Pauses Preparations for Phase 3 Trial in Dlb

THOMSON REUTERS
·
10 Dec 2024

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

GlobeNewswire
·
10 Dec 2024

CervoMed initiated with Buy into ‘binary readout’ at Roth MKM

TIPRANKS
·
06 Dec 2024

HC Wainwright Initiates CervoMed at Buy With $42 Price Target

MT Newswires Live
·
05 Dec 2024

CervoMed Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
05 Dec 2024

CervoMed initiated with a Buy at H.C. Wainwright

TIPRANKS
·
05 Dec 2024

CervoMed Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $42

THOMSON REUTERS
·
05 Dec 2024

CervoMed Enhances Transparency with Key Information Access

TIPRANKS
·
03 Dec 2024

CervoMed Is Maintained at Buy by D. Boral Capital

Dow Jones
·
27 Nov 2024

CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod

Dow Jones
·
27 Nov 2024